Abstract
Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have